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Swiss multicenter study evaluating the efficacy, feasibility and
safety of peginterferon-alfa-2a and ribavirin in patients with
chronic hepatitis C in official opiate substitution programs
Abstract
BACKGROUND: Though patients in opiate substitution programs are commonly infected with HCV,
due to safety and efficacy concerns, they are rarely treated with interferon and ribavirin. METHODS: In
a multicenter study, HCV-infected patients in opiate maintenance treatment programs received 180
microg pegylated interferon-alfa-2a once weekly, plus daily ribavirin for 24 weeks (genotypes 2, 3), or
48 weeks (genotypes 1, 4). RESULTS: Of the 67 patients enrolled, 31 (46%) had HCV genotypes 1 or 4,
and 36 (54%) had genotypes 2 or 3. Intent-to-treat analysis showed end-of-treatment virologic response
in 75% of patients (81% of genotypes 2 or 3; 65% of genotypes 1 or 4), and a sustained virologic
response in 61% of patients (72% of genotypes 2 or 3; 48% of genotypes 1 or 4). Fifteen patients (22%)
did not complete the study, in 5 (8%) cases because of severe adverse events. CONCLUSIONS: Drug
users with chronic HCV infection, regularly attending an opiate maintenance program in which close
collaboration between hepatologists/internists and addiction specialists is assured, can be treated
effectively and safely with pegylated interferon-alfa-2a and ribavirin. Treatment results are very similar
to those in other patient groups, and thus therapy should also be considered for this population. 
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an opiate maintenance program in which close collabora-
tion between hepatologists/internists and addiction spe-
cialists is assured, can be treated effectively and safely with 
pegylated interferon-alfa-2a and ribavirin. Treatment results 
are very similar to those in other patient groups, and thus 
therapy should also be considered for this population. 
 Copyright © 2008 S. Karger AG, Basel 
 Introduction 
 Hepatitis C virus (HCV) infection causes chronic hep-
atitis in approximately 85% of those infected, and up to 
20% of these develop liver cirrhosis as a late sequela  [1] . 
Intravenous drug users (IDU) represent the core of the 
hepatitis C epidemic in the developed world. The litera-
ture cites infection percentages ranging from between 60 
and even up to 100% of IDU being chronically infected, 
depending upon the individual’s risk behavior and dura-
tion of intravenous drug use  [2–8] . Viral transmission is 
still uncontrolled among IDU  [8–12] . Seroprevalence in 
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 Abstract 
 Background: Though patients in opiate substitution pro-
grams are commonly infected with HCV, due to safety and 
efficacy concerns, they are rarely treated with interferon and 
ribavirin.  Methods: In a multicenter study, HCV-infected pa-
tients in opiate maintenance treatment programs received 
180   g pegylated interferon-alfa-2a once weekly, plus daily 
ribavirin for 24 weeks (genotypes 2, 3), or 48 weeks (geno-
types 1, 4).  Results: Of the 67 patients enrolled, 31 (46%) had 
HCV genotypes 1 or 4, and 36 (54%) had genotypes 2 or 3. 
Intent-to-treat analysis showed end-of-treatment virologic 
response in 75% of patients (81% of genotypes 2 or 3; 65% of 
genotypes 1 or 4), and a sustained virologic response in 61% 
of patients (72% of genotypes 2 or 3; 48% of genotypes 1 or 
4). Fifteen patients (22%) did not complete the study, in 5 
(8%) cases because of severe adverse events.  Conclusions: 
Drug users with chronic HCV infection, regularly attending 
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the general population ranges between 0.2 and 2%. For 
Switzerland, estimates range from 0.5 to 1% of the popu-
lation  [13] .
 In many cases, depending on viral genotype, antiviral 
therapy of HCV infection with standard interferon-alfa 
(SIF) plus ribavirin (RBV) achieves sustained virologic 
response (SVR). The introduction of pegylated interfer-
ons (PEG-IFN) has further improved treatment respons-
es  [14–18] . 
 The treatment of chronic hepatitis C in drug users re-
mains controversial. Various national and international 
guidelines and consensus recommendations have exclud-
ed drug users from anti-HCV therapy  [19, 20] , whereas 
others have questioned this reasoning  [3, 6, 21–23] . 
 It was only in 2002 that the National Institute of Health 
consensus on medical management of HCV infection 
changed its recommendation to now consider treatment 
of IDU on a case-by-case basis  [24] . Despite these newer 
recommendations, IDU still face many obstacles to HCV 
treatment, few have access to HCV treatment, and they 
are less frequently treated than other patient groups  [25, 
26] .
 The main reasons mentioned for excluding drug users 
from HCV treatment are the following:
 • Presumed inadequate compliance; 
 • High rate of mainly psychological side effects; 
 • Risk of re-infection; 
 • Co-infection with hepatitis B or HIV; 
 • Treatment of HCV only after successful detoxifica-
tion; 
 • Presence of contraindications for HCV treatment. 
 It has been shown  [22, 23, 25, 27–30] that in the setting 
of opiate maintenance treatment (OMT; with metha-
done, heroin, buprenorphine or other opiates), HCV 
treatment with interferon (IFN) and ribavirin is feasible 
and safe, at least in small, highly selected groups of pa-
tients.
 We conducted an open-label, phase IIIb multicenter 
study of HCV treatment with pegylated interferon-alfa-
2a plus ribavirin in drug users undergoing opiate main-
tenance treatment in Switzerland. The primary objective 
was to evaluate the efficacy of pegylated interferon-alfa-
2a in combination with ribavirin in a relatively unselect-
ed group of chronic hepatitis C (CHC) patients partici-
pating in opiate substitution programs. 
 Secondary objectives were:
 • To evaluate the efficacy of PEG-IFN plus RBV on the 
reduction of HCV viraemia after 4, 12, 24 and 48 
weeks; 
 • To evaluate the efficacy of the combination therapy 
according to genotype and viral load of hepatitis C;  
 • To evaluate the efficacy of the combination therapy 
depending on patient’s previous IFN treatment; 
 • To evaluate the safety of PEG-IFN plus RBV in pa-
tients with CHC participating in opiate substitution 
programs; 
 • To assess adherence to therapy during treatment with 
PEG-IFN plus RBV for patients participating in opiate 
substitution programs. 
 Patients and Methods 
 Centers and Screening 
 Eleven Swiss centers took part in the study. Most centers offer 
two forms of opiate substitution programs: oral substitution 
(methadone or buprenorphine) with a low threshold (evidence of 
dependence and two previous withdrawal attempts), and intrave-
nous diacetylmorphine (heroin) substitution with high threshold 
criteria  [31] . 
 HCV antibody testing is offered, and in most cases performed, 
at the start of the opiate substitution treatment. Screening for par-
ticipating in the HCV treatment study started only when adher-
ence to maintenance treatment was achieved and chronic hepati-
tis was confirmed. During the screening phase, none of the pa-
tients had signs or symptoms suggesting acute HCV infection. 
 The patients provided their written informed consent to par-
ticipate in the study, which had been previously approved by the 
local institutional review boards and conformed to the ethical 
guidelines of the 1975 Declaration of Helsinki.
 Patient Selection 
 Men and women between 18 and 65 years of age, with sero-
logically proven chronic hepatitis C and participating in an offi-
cial opiate maintenance treatment program, but not previously 
treated with interferon-ribavirin combination therapy, were eli-
gible for screening. During the screening phase, within 28 days 
prior to the first dose of pegylated interferon-alfa-2a and ribavi-
rin, examinations established patient eligibility according to the 
inclusion/exclusion criteria. 
 Inclusion criteria were:
 • Serum HCV PCR  1 600 IU/ml (COBAS Amplicor Monitor 
HCV RNS 2.0; Hoffmann-La Roche);  
 • Elevated serum ALT documented on at least one occasion 
within the past 6 months; 
 • Compensated liver disease (Child Pugh Grade A clinical clas-
sification in the case of cirrhosis); 
 • Ultrasound or MRI with no evidence of hepatocellular carci-
noma; 
 • Serum AFP  ! 100 ng/ml and regular attendance at the treat-
ment center.  
 A liver biopsy was not required on study entry, and other 
causes of liver disease were excluded by appropriate laboratory 
tests (anti-HAV IgM Ab, HBs-Ag, anti-HBc IgM-Ab; coeruloplas-
min, ferritin, transferrin saturation; ANA, AMA). 
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 A noninvasive index, the AST to platelet ratio index (APRI), 
was calculated to estimate the percentage of patients with severe 
fibrosis or cirrhosis  [32] . 
 Patients were excluded from participation if they had:
 • Neutropenia ( ! 1,500 neutrophils/mm 3 );  
 • Thrombocytopenia ( ! 90,000 platelets/mm 3 );  
 • Anaemia ( ! 12 g Hg/dl in women and  ! 13 g Hg/dl in men);  
 • Human immunodeficiency virus (HIV) infection;  
 • Chronic hepatitis B;  
 • Decompensated liver disease;  
 • A serum creatinine level  1 1.5 times the upper limit of nor-
mal;  
 • Poorly controlled psychiatric disease;  
 • Substantial coexisting medical conditions;  
 • Were pregnant or breast feeding, or male partners of a preg-
nant woman. 
 Further exclusion criteria were:  
 • Therapy with any systemic antiviral, antineoplastic or immu-
nomodulatory treatment within 6 months prior to the first 
dose of study drug, or with any investigational drug within 6 
weeks prior to the first dose of study drug;  
 • Evidence of drug abuse including excessive alcohol consump-
tion outside the official opiate substitution program;  
 • And inability or unwillingness to provide informed consent 
or abide by the requirements of this study. 
 Treatment 
 In this open-label, phase IIIb multicenter study, patients re-
ceived once-weekly subcutaneous injections of 180   g pegylated 
interferon-alfa-2a, usually administered by a study nurse in the 
opiate maintenance treatment centers, plus daily ribavirin. In pa-
tients with genotype 2 or 3, treatment was given for 24 weeks and 
the ribavirin dose was 800 mg/day. In patients with genotype 1 
and 4, treatment was given for 48 weeks; the ribavirin dose was 
1,000 mg/day for patients weighing  ! 75 kg, and 1,200 mg/day for 
those weighing  1 75 kg. Clinical visits and laboratory investiga-
tions were performed at the screening visit 4 weeks before base-
line, at baseline, and at weeks 1, 2, 4, 6, 8 and 12, and then every 
6 weeks until 6 months after the end of treatment. Viremia was 
measured at weeks 4 and 12, at the end of treatment, and 6 months 
after the end of treatment. 
 Subsidiary endpoints were:
 • Side effects, which were WHO graded;  
 • Dose reductions;  
 • Treatment interruptions;  
 • And dropouts.  
 Patients with no early virologic response at 12 weeks (RNA 
negativity or a drop in viral load by more than two logs) were 
given the option to discontinue treatment. In case of intolerance 
to study medication, doses were adjusted according to guidelines. 
HCV PCR was performed by local and approved laboratories us-
ing COBAS Amplicor Monitor HCV RNS 2.0 (Hoffmann-La 
Roche); HCV genotyping was performed with INNO Lipa HCV 
II (Bayer).
 Most patients received all of their study medication at the 
same center where they received opiate substitution treatment. 
Those patients considered reliable enough to administer pegylat-
ed interferon-alfa-2a themselves were asked to return all used vi-
als. All patients were asked to return open bottles, and tablet 
counts were made at each visit. Patients were considered compli-
ant if they had taken at least 80% of the study medication for 80% 
of the planned treatment period.
 Ribavirin was provided by Roche Pharma, Switzerland. 
 Statistics 
 The primary end-point of the study was a sustained virologic 
response to combined therapy, defined as a negative quantitative 
HCV-RNA determination 24 weeks after the end of treatment. All 
end-points were evaluated in an intent-to-treat analysis, includ-
ing all patients who received at least one dose of study medication. 
Non-parametric tests were used for comparison of groups.
 Results 
 Patient Demographics 
 Between March 2002 and June 2004, 67 patients from 
11 treatment centers were enrolled in the study and re-
ceived at least one dose of study medications. Of these, 49 
were male, 18 were female; the mean age was 34 years. At 
baseline, 52 of 67 patients were receiving maintenance 
treatment with methadone alone, 7 used heroin and 
methadone, 3 only heroin, and 5 other opioids (buprenor-
phine or oral morphine). The mean duration of intrave-
nous drug addiction was 156.7  8 59 months. The esti-
mated duration of HCV infection was 132.5  8 74.9 
months. Based on the APRI index (cut-off value  1 1.5), the 
estimated percentage of patients with severe fibrosis or 
cirrhosis was 25%.
 Further pretreatment characteristics of the patients 
are summarized in  table 1 .
 Virologic Response 
 In the intention-to-treat analysis, 75% of patients had 
nondetectable HCV RNA at the end of treatment (geno-
types 2 and 3: 81%; genotypes 1 and 4: 65%). Some 61% of 
patients (genotypes 2 and 3: 72%; genotypes 1 and 4: 48%) 
had a sustained virologic response 24 weeks after the end 
of treatment. Rapid virologic response at week 4 and ear-
ly virologic response at week 12 are shown in  figure 1 . 
End of treatment response (75%) was lower than early vi-
rologic response (84%) because three patients experi-
enced a breakthrough of HCV viremia during treatment 
and 2 patients dropped out during this phase of the 
study.
 Patients who achieved SVR had been on opiate substi-
tution for a shorter period (139.4  8 61 vs. 183.9  8 82 
months, p = 0.0164) than those with no SVR. This may 
reflect a shorter duration of HCV infection, which is one 
of the predictors of response.
 Fried et al. Digestion 2008;78:123–130126
 Patients with a pretreatment HCV RNA level of 
 ^  500,000 IU/ml (n = 30, SVR 77%) had a significantly 
better treatment response than those with a pretreatment 
HCV RNA level of  1 500,000 IU/ml (n = 37, SVR 49%,
p = 0.02).
 Of the 67 patients, four (three genotype 1, one geno-
type 2) had previously been treated unsuccessfully with 
interferon monotherapy. None of these patients achieved 
SVR.
 Predictive Value of Early Virologic Response 
 By week 12, 84% (56/67)  of the patients treated with 
peginterferon-alfa-2a plus ribavirin showed an early vi-
rologic response, defined as no detectable serum HCV 
RNA or a drop in viral load by more than two logs ( fig. 2 ). 
Of those with early virologic response, 71% subsequently 
had a sustained virologic response. In contrast, among 
the 11 patients who did not have an early virologic re-
sponse, 10 (negative predictive value, NPV = 91%) did not 
have a sustained virologic response.
 Safety 
 From the 67 patients entering the study, 83% (6 discon-
tinuations) with genotype 2 or 3, and 69% (9 discontinu-
ations) of those with genotype 1 or 4, completed the study 
as planned. Premature study termination due to adverse 
events was observed in 5 (8%) of the patients ( table 2 ).
 Dose modifications due to adverse events were fre-
quently necessary (not all data shown). Only 37% of pa-
tients continued full treatment doses of pegylated inter-
feron-alfa-2a and ribavirin. The need for ribavirin dose 
reduction was significantly more frequent in patients 
Table 1. Characteristics of patient population
Mean age, years (range) 34 (21–56)
Male/female, n (%) 49 (73)/18 (27)
Weight, kg 73.6816.5
BMI 25.085.0
ALT, U/l 112884
Normal ALT 18%
ALT 1-2 ULN 46%
ALT 2–3 ULN 13%
ALT > ULN 22%
Thrombocytes <150,000/l 12%
APRI score [32]
>1.5, n (%) 17 (25)
>2.0, n (%) 9 (13)
HCV RNA level, kIU/ml 2,57185,021
≤500,000 IU/ml 30 (45%)
>500,000 IU/ml 37 (55%)
HCV genotype, n (%)
Genotype 1 25 (37)
Genotype 2 2 (3)
Genotype 3 34 (51)
Genotype 4 6 (9)
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 Fig. 1. Viral response rates. Virologic response at weeks 4 and 12, 
end-of-treatment (EOT) virologic response and sustained viro-
logic response (SVR), according to intention-to-treat analysis. A 
virologic response was defined as an undetectable level of HCV 
RNA ( ! 600 IU/ml). 
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 Fig. 2. Predictability of sustained virologic response. At week 12, 
84% (56 of 67) of the patients treated with peginterferon-alfa-2a 
plus ribavirin had an early virologic response (RNA negativity or 
a drop in viral load by more than two logs). Of these patients, 71% 
(40 of 56) went on to have a sustained virologic response (SVR). 
Of the 11 patients who did not have an early virologic response at 
week 12, 10 (91%) did not have a sustained virologic response. 
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treated for 48 weeks (i.e. with genotypes 1 or 4) than in 
those treated for 24 weeks (69% vs. 40%, p = 0.039), where-
as the need for dose reduction of pegylated interferon-
alfa-2a did not significantly differ between the groups 
(overall 55%, p = 0.09). Though adverse events were seen 
in most patients, the most common reasons leading to 
dose reductions were granulocytopenia (6), thrombocy-
topenia (5), anemia (5), and a flu-like syndrome (2) ( ta-
ble 3 ).
 Most adverse events were those commonly associated 
with interferon-based treatment ( table 3 ). There were 188 
events that occurred in the 36 patients treated for 24 
weeks (genotypes 2 or 3), and 171 events were reported in 
the 31 patients treated for 48 weeks (genotypes 1 or 4). 
Severe adverse events (WHO grade 3 or 4) being reported 
more than once were neutropenia (3), thrombopenia (2), 
fatigue (3), anorexia (2), and headache (2). Psychiatric side 
effects grades 3 or 4 were rare. One severe episode of de-
pression, one panic attack and one psychotic disorder 
were recorded. Rarely did serious adverse events lead to 
termination of the study (5 patients).
 Concomitant Medications 
 Concomitant medications were prescribed for 77% of 
all patients at some point during the study. In particular, 
10 patients (15%) were taking antidepressants at entry 
and a further 15 patients (23%) received antidepressants 
during the study for treatment of side effects. Two pa-
tients (3%) took benzodiazepines at entry and a further 
10 patients (15%) received benzodiazepines during the 
course of the study.
 Discussion 
 The treatment of HCV-infected patients who continue 
to take opiates, even in the setting of an opiate mainte-
nance treatment program, is still a matter of debate. In 
this study, we report the results of treatment with pe-
gylated interferon-alfa-2a plus ribavirin. As was observed 
in earlier studies, only a selected group of patients in opi-
ate maintenance treatment were included. Among ap-
proximately 1,700 substituted patients at eleven Swiss 
treatment centers, 67 started treatment with pegylated 
interferon-alfa-2a plus ribavirin. Recruitment was slow 
and took longer than expected. The reasons for non-
treatment were not assessed in the actual study, but were, 
in general, either patient- and/or physician-related. Nev-
ertheless, in this setting, antiviral treatment with peg-
ylated interferon-alfa-2a plus ribavirin proved feasible 
and safe. Efficacy, measured as SVR, was 61% across all 
virus genotypes. Compared to an overall sustained viral 
response of 47% in an earlier study with standard inter-
feron and ribavirin in the same setting  [30] , the treatment 
response rate with pegylated interferon-alfa-2a was clear-
Table 2. Reasons for premature study withdrawal
Genotype 2, 3 Genotype 1, 4 All
Adverse events 2 3 5
Lost to follow-up 2 0 2
Withdrawn consent 2 1 3
Other 0 3 3
NR after week 12 – 2 2
Total 6 9 15
Table 3. Incidence of adverse events (occurring in more than 
5%)
Blood system disorders overall1 12 (19%)
Neutropenia/granulocytopenia 6
Thrombocytopenia 5
Anemia 5
Eye disorders overall1 (various) 6 (9%)
Gastrointestinal disorders overall1 28 (42%)
Nausea 12
Vomiting 8
Abdominal pain 5
Upper abdominal pain 5
Dyspepsia 4
Nervous system disorders overall1 27 (40%)
Headache 21
Psychiatric disorders1 31 (46%)
Depression 20
Insomnia 14
Thoracic disorders1 9
Skin disorders overall1 28 (42%)
Alopecia 10
Pruritus 10
Dry skin 5
General disorders1 42 (63%)
Fatigue 29
Flu-like symptoms 27
Irritability 8
Injection site erythema 5
Concomitant infections 18
Anorexia 9
Musculoskeletal pain 9
1 Patients with at least one AE.
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ly higher, as has been shown in studies using the same 
therapies but requiring cessation of opiate use  [18] . Pa-
tients with genotype 2 or 3 had a sustained virologic re-
sponse rate of 72%; those with genotype 1 or 4 had an 
SVR of 48%. These response rates are very similar to 
those from previous studies requiring cessation of opiate 
use  [15, 18] .
 A reappearance of HCV after early virologic response 
was observed in five patients. Most likely, this was due to 
a breakthrough and not to reinfection. No patient re-
lapsed to i.v. drug use for the duration of the study. Even 
if individual patients had been injecting drugs during the 
course of the study, they most likely would have used 
clean needles and syringes, which are easily available in 
Switzerland. 
 Early prediction of virologic response to interferon-
based therapy can help identify patients unlikely to have 
a sustained response, and allow clinicians the option to 
discontinue treatment, thereby saving patients side ef-
fects and cost of additional therapy. There is now a con-
sensus that treatment should be discontinued in patients 
who do not achieve early virologic response by week 12 
 [33] . The current study suggests that this also holds true 
for opiate substituted patients: 91% of our patients who 
did not have an early virologic response by week 12 did 
not achieve a sustained virologic response. These results 
are very similar to those in larger studies involving non-
IDU patients.
 One of the reasons for the reluctance of hepatologists 
to treat IDU with HCV infection is a supposed noncom-
pliance and a higher rate of dropouts from treatment pro-
grams. In a previous treatment study with pegylated in-
terferon-alfa-2b plus ribavirin in patients on methadone 
maintenance, sustained virologic response was 42% in 
the methadone group, and thus lower, though not statisti-
cally significantly so, than the 56% in the control group 
(p = 0.16). The main reason for this difference appeared 
to be a higher rate of early treatment discontinuation 
within the first 8 weeks due to non-compliance or patient 
request  [34] . In a recent paper, Guadagnino et al.  [35] 
showed that patients treated in a multidisciplinary man-
agement model had treatment responses not different 
from those achieved in non-IDU patients. Other, retro-
spective studies found similar compliance rates and re-
sponses to therapy among IDU and non-IDU patients 
 [36] . Treatment compliance rates for IDU in other chron-
ic diseases, such as tuberculosis or HIV  [37] , are similar 
to cohorts of non-IDU, and healthcare providers cannot 
reliably predict patients who are likely to be compliant 
with the prescribed regimen. Previous studies have indi-
cated that active IDU with CHC infection can achieve an 
SVR, particularly if they comply with at least two-thirds 
of their scheduled clinic visits, and are attending a mul-
tidisciplinary clinic that includes both hepatologists/in-
ternists and specialists in addiction medicine  [27–29] . In 
our study, patients were treated at the same center where 
they also received opiate maintenance treatment, further 
assuring compliance with scheduled visits.
 Side effects of treatment were common in this study; 
however, serious side effects leading to premature with-
drawal occurred in less than 10% of patients (5 of 67). The 
side effects did not differ in character or frequency from 
those of earlier published studies with treatment using 
pegylated interferon and ribavirin. Serious psychiatric 
side effects were very rare. This may be due to the fact that 
patients received antidepressants and/or benzodiaze-
pines as deemed necessary by the treating physician. 
Overall, at some point during the study, 38% of patients 
were prescribed antidepressants and 18% benzodiaze-
pines.
 Some limitations apply to the results of this study. Al-
though our findings are encouraging, the number of 
treated patients was small and we did not include a con-
trol group of non-IDU patients. We also did not assess 
why more patients in opiate maintenance treatment pro-
grams did not receive HCV treatment. Clearly, there is a 
selection bias, although the same can be said for treat-
ment studies in non-IDU patients  [38] . In a previous 
screening study among Swiss patients on opiate mainte-
nance treatment, the type and distribution of reasons for 
nonparticipation of hepatitis C seropositive candidates 
were assessed using a semistructured questionnaire  [39] . 
In less than half of all candidates, a decision for or against 
treatment was actually made. The rest had either a nega-
tive hepatitis C serology, or other reasons were given for 
nonparticipation. Some 80% of the reasons for nonpar-
ticipation in the treatment study were based on protocol 
issues. The three most frequent were normal liver values, 
co-infection with HIV, and negative HCV RNA. These 
together accounted for nearly half of all protocol-based 
refusals.
 In our earlier study  [30] , only 6% of all infected pa-
tients were eligible for treatment; indeed, a recently pub-
lished study cited an even lower percentage  [6] . Our study 
is therefore not able to answer the important question of 
whether treating a larger proportion of HCV infected 
IDU and using less stringent selection criteria would still 
be effective and safe. Also, we cannot answer the question 
as to which elements of addiction treatment programs, 
which patient characteristics, or what type of collabora-
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tion model between hepatologists and physicians pre-
scribing opiates are critical for success. In this context, we 
should not forget that in Switzerland and several other 
countries, many patients receive their opiate mainte-
nance treatment through primary care physicians, and 
that thoughts about collaboration models should include 
these groups. As do others, we believe that the need for 
such research is urgent in the view of the high prevalence 
of HCV infection among this population.
 In summary, our results indicate that HCV therapy of 
patients treated in opiate treatment programs with pe-
gylated interferon-alfa-2a plus ribavirin is feasible, safe 
and efficacious, with SVR rates similar to those from pre-
vious studies in non-IDU patients. Close collaboration 
between hepatologists/internists and specialists in the 
treatment of addiction seems to be important, and pa-
tients should preferably be treated in a setting where they 
also receive opiate maintenance treatment. Further com-
munity-based studies are required to better define the 
natural history of the disease, and to determine the safest 
and most effective treatment regimen for this group of 
patients. Better strategies should be developed to include 
more IDU patients in HCV treatment programs. En-
hanced collaboration between hepatologists and special-
ists in treatment of addiction should be encouraged. For 
that purpose, the allocation of more resources in terms of 
funding and manpower is an imperative and would allow 
treatment of larger numbers of IDU patients. Indeed, 
IDU patients now constitute a large part of the HCV-in-
fected population in most countries of the developed 
world.
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